Pulse Biosciences, Inc. (PLSE) Earnings Call Transcripts

Pulse Biosciences, Inc.'s Latest Earnings Call - June 10, 2026

In Q2 2026, Pulse Biosciences, Inc. focused on its unique NanoPulse technology, particularly in the atrial fibrillation (AF) market. The company did not disclose specific revenue or earnings figures in the call, but emphasized its strategic pivot towards electrophysiology (EP) applications, highlighting a '96% efficacy as it relates to AFib freedom at 12 months.' Management did not provide explicit financial guidance but indicated accelerated enrollment in their U.S. IDE study, aiming for early 2028 market entry.

Reported metrics

Guidance from management

Management aims for early 2028 U.S. market entry for its AFib treatment, with accelerated IDE enrollment expected to complete by October 2026. No specific financial guidance was provided.

What management said

Well, only that, that is -- we agree with that, number one. Number two, it's based upon a lot of data, a lot of studies that are deriving from the efficacy. If PFA addresses cells and those cells are turned off, then what are you going to see from month 4 to month 7 to month 9? And at some point, there is diminishing value in following longer term, and you can use the power of some patients followed a year to inform ...

But that's only recent. I think you should bear in mind that, that trend inverted with the arrival of FARAPULSE as the first-generation PFA device. Prior to that, it was mapping led and followed by ablation.

What analysts pressed on

Analysts are concerned about the competitive landscape in the EP market and the potential challenges in executing a successful partnership strategy. There is also interest in how the company plans to manage resource allocation across multiple therapeutic areas.

Main topics on the call

• NanoPulse Technology — Pulse Biosciences emphasized its NanoPulse technology as a differentiated form of pulsed field ablation (PFA), claiming it offers 'a different and much more efficient way of treating cells.' The technology is positioned ...
• Atrial Fibrillation Focus — The company is concentrating resources on atrial fibrillation, citing '96% efficacy as it relates to AFib freedom at 12 months,' which is significantly higher than competitors. This focus is expected to drive growth in t...
• Partnership Strategy — Pulse Biosciences plans to use a partnership strategy to enter large markets like EP, leveraging its technology's unique attributes to attract partners. 'Partnership dynamics are natural,' according to management.
• Regulatory and Clinical Progress — The company has treated over 175 patients in feasibility studies and is progressing with a U.S. IDE study, aiming for early 2028 market entry. Management highlighted 'a relatively conventional pivotal study' with a focus...

Read the full Pulse Biosciences, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 34 Pulse Biosciences, Inc. earnings call transcripts on record, spanning February 18, 2020 to June 10, 2026. Based on this history, Pulse Biosciences, Inc. reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PLSE

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

34

First call

February 18, 2020

Most recent

June 10, 2026

Reporting cadence

quarterly